Search Results

You are looking at 121 - 130 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value

Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman

emetogenic chemotherapy, multidrug chemotherapy regimens in patients for whom single agents will suffice, routine surveillance PET scans, prostate-specific antigen screening in patients with an expected lifespan of less than 10 years, and the use of targeted

Full access

Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer

Claudia S.E.W. Schuurhuizen, Patricia Marino, Annemarie M.J. Braamse, Laurien M. Buffart, Florence Joly, Karim Fizazi, Muriel Habibian, Jean-Marie Boher, Michel Soulie, Stéphane Oudard, Inge R.H.M. Konings, Henk M.W. Verheul, Joost Dekker, and Gwenaelle Gravis

structure beyond the spine or pelvis), 19 serum concentration of prostate-specific antigen at treatment initiation (<65 or ≥65 ng/mL), and Gleason score at baseline (2–6 vs 7 vs 8–10). Unstandardized (B) and standardized regression coefficients (β) and 95

Full access

Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer

Kazzem Gheybi, Jue Jiang, Shingai B.A. Mutambirwa, Pamela X.Y. Soh, Zsofia Kote-Jarai, Weerachai Jaratlerdsiri, Rosalind A. Eeles, M.S. Riana Bornman, and Vanessa M. Hayes

, 45–99 years); a prostate-specific antigen (PSA) level of 370 ng/mL (range, 8–4,841 ng/mL) at diagnosis; and a family history of prostate or any cancer ( Table 1 ). The elevated PSA levels observed within our study cohort have previously been reported

Full access

Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer

Xudong Ni, Michael Luu, Weiwei Ma, Tingwei Zhang, Yu Wei, Stephen J. Freedland, Dingwei Ye, Timothy J. Daskivich, and Yao Zhu

such as age, prostate-specific antigen (PSA), Gleason score, ECOG status, and socioeconomic status, patient-level data were balanced by propensity score matching (PSM) before analyses. Methods We sampled physiologic males with de novo metastatic

Full access

Inherited Mutations in Chinese Men With Prostate Cancer

Yao Zhu, Yu Wei, Hao Zeng, Yonghong Li, Chi-Fai Ng, Fangjian Zhou, Caiyun He, Guangxi Sun, Yuchao Ni, Peter K.F. Chiu, Jeremy Y.C. Teoh, Beihe Wang, Jian Pan, Fangning Wan, Bo Dai, Xiaojian Qin, Guowen Lin, Hualei Gan, Junlong Wu, and Dingwei Ye

in a first-degree relative (36.2% vs 19.5%; P <.001) ( Table 1 ). There was no difference between patients with mutations in ATM / BRCA / MSH2 / PALB2 and noncarriers in prostate-specific antigen at diagnosis ( P =.2), TNM classification, and NCCN

Full access

Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer

Boshen Jiao, Yaw A. Nyame, Josh J. Carlson, Louis P. Garrison Jr, and Anirban Basu

test the robustness of the analysis. First, we included prostate-specific antigen (PSA) level as an additional covariate; it was not included in the primary analysis because nearly half of the men lacked this information. Second, we excluded the men who

Full access

New Agents in Metastatic Prostate Cancer

Atish D. Choudhury and Philip W. Kantoff

progression-free survival (5.6 vs. 3.6 months; P <.001) and prostate-specific antigen (PSA) response rate (29% vs. 6%; P <.001). In prior studies, 11 treatment with abiraterone was accompanied by signs and symptoms of mineralocorticoid excess (hypertension

Full access

Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review

Jenna F. Borkenhagen, Daniel Eastwood, Deepak Kilari, William A. See, Jonathan D. Van Wickle, Colleen A. Lawton, and William A. Hall

diagnosis: Gleason score >7, prostate-specific antigen (PSA) level >20 ng/mL, or clinical stage T3a–T4. 2 Curative-intent therapy was filtered for based on radiation dose thresholds. Patients outside the age range of 18 to 90 years were excluded. The high

Full access

Carcinoma of Unknown Primary: Focused Evaluation

Gauri R. Varadhachary

rather referral bias and suboptimal evaluation before CUP designation). Serum Tumor Markers and Cytogenetics Men presenting with adenocarcinoma and bone metastases should have their serum prostate-specific antigen (PSA) level evaluated for

Full access

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma

James J. Harding, Ghaith Abu-Zeinah, Joanne F. Chou, Dwight Hall Owen, Michele Ly, Maeve Aine Lowery, Marinela Capanu, Richard Do, Nancy E. Kemeny, Eileen M. O'Reilly, Leonard B. Saltz, and Ghassan K. Abou-Alfa

-refractory metastatic prostate cancer . Urology 2007 ; 70 : 315 – 319 . 32. Saad F Segal S Eastham J . Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without